FDA Approval Process Explained

The 6 major regulatory milestones

1. IND (Investigational New Drug) filing: Permission to start human trials. Granted by default if FDA doesn't object within 30 days. Modest stock impact.
2. End-of-Phase 2 meeting: FDA agrees on Phase 3 trial design. Critical de-risking event; stock often moves 5-20% on the announcement.
3. Special Protocol Assessment (SPA): Optional. FDA pre-approves the Phase 3 protocol so positive results meet pre-agreed approval bar. Strong de-risking.
4. NDA / BLA filing: Application for approval. Significant milestone; stock often moves 10-30% on filing.
5. PDUFA date: FDA decision deadline. See our PDUFA guide.
6. Label finalization: Even after approval, the specific indication, dosing, and warnings on the label affect commercial potential. Sometimes leads to "sell the news" if label is narrower than expected.

Special FDA designations

• Fast Track: Faster review for serious unmet need. Modest impact.
• Breakthrough Therapy: Intensive FDA guidance + faster review for substantial improvement over existing therapy. Strong positive signal; stock often moves 20-50%.
• Priority Review: 6-month review instead of 10-month. Stock impact moderate.
• Accelerated Approval: Approval based on surrogate endpoints with confirmatory Phase 4 required. Common in oncology and rare disease. Strong positive but with confirmatory-trial risk.
• Orphan Drug Designation: 7-year market exclusivity, tax credits, fee waivers for rare diseases. Modest direct impact but can transform commercial value.

What can go wrong at each stage

• IND clinical hold: FDA stops a trial pre-start due to safety concerns. Major negative signal.
• EOP2 disagreement: FDA wants different Phase 3 design than company proposed. Adds time/cost; often −10% to −30% reaction.
• Refuse-to-File: FDA returns NDA without reviewing because filing is incomplete. Major embarrassment; significant stock impact.
• Complete Response Letter: FDA says no. Worst case for catalyst trader.
• Post-approval label restrictions: Black-box warnings, REMS programs, or narrow labels reduce commercial potential.

Resources for tracking the process

• FDA Drug Approvals page — official approvals, lagging
• FDA Calendar — upcoming AdCom meetings
• SEC EDGAR — companies file 8-Ks for material FDA interactions
• Clinical Investor catalyst calendar — synthesizes all of the above into a single feed with stock-impact analysis

Frequently Asked Questions

How long does FDA approval take?

From IND filing to NDA approval, the median is about 10 years. Phase 1 alone takes 1-2 years; Phase 2, 2-3 years; Phase 3, 3-5 years; FDA review, 6-10 months.

Can the FDA approve a drug after rejecting it?

Yes — companies frequently address Complete Response Letter (CRL) deficiencies and re-submit. About 40-50% of drugs that receive a CRL are approved on subsequent review.

What's the difference between full approval and accelerated approval?

Accelerated approval is granted based on surrogate endpoints (e.g., tumor shrinkage instead of survival) for serious diseases with unmet need. The company must conduct confirmatory Phase 4 trials. If those fail, the drug can be withdrawn.

Why do some drugs get approved in Europe but not the US?

EMA (European) and FDA approval are independent processes with different criteria. EMA tends to weight risk-benefit slightly differently and has different sample-size and endpoint requirements. Drugs approved by one but not the other are common.

Related guides

• How to Read a Clinical Trial
• PDUFA Dates: Investor's Guide
• How to Invest in Biotech
• Biotech Catalyst Trading Strategy
• Clinical Trial Phases (1, 2, 3) Explained
• How to Evaluate a Biotech Pipeline
• Biotech IPO Investor Guide